Dong-ki Lee

Company: OliX Pharmaceuticals

Job title: Founder & Chief Executive Officer

Seminars:

Asymmetric siRNA Therapeutics Targeting Skin, Eye, & Liver Diseases 11:00 am

RNAi therapeutics have the potential to target hepatic as well as extra-hepatic diseases with the use of optimal delivery methods. We have established lipid-conjugated asymmetric siRNA (asiRNA) targeting skin and ocular tissues to develop therapeutic programs against the hypertrophic scar, androgenic alopecia, and age-related macular degeneration. We also present a GalNAc-based liver targeting strategy to…Read more

day: Pre-Conference Day